Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tenaya Therapeutics, Inc. (NASDAQ: TNYA) SEC filings page provides access to the company’s publicly filed documents, including current reports on Form 8-K and other registration materials related to its clinical-stage biotechnology activities. Tenaya describes itself as a clinical-stage company developing gene therapies and a small molecule HDAC6 inhibitor that address the underlying drivers of heart disease, and its filings offer additional detail on these efforts.
Through its SEC reports, Tenaya discloses material events such as underwritten public offerings, clinical program updates and financial results. For example, a Form 8-K dated December 11, 2025, outlines the terms of an underwritten public offering of units consisting of common stock and warrants, including expected gross proceeds and key conditions. Other 8-K filings reference quarterly financial results and communications with the U.S. Food and Drug Administration regarding the MyPEAK-1 trial of TN-201.
Investors can use these filings to better understand capital structure changes, including equity offerings and warrant terms, as well as regulatory and clinical milestones that the company reports to the market. The filings also confirm Tenaya’s exchange listing on the Nasdaq Global Select Market under the symbol TNYA and describe the nature of its business as a clinical-stage biotechnology company focused on therapies for genetic cardiomyopathies and heart failure.
On Stock Titan, Tenaya’s filings are paired with AI-powered summaries that highlight key points from documents such as Form 8-K current reports and registration statements. This can help readers quickly identify the main elements of financing transactions, clinical trial disclosures and other material events, while still allowing full access to the original SEC text for detailed review.
Tenaya Therapeutics files its Annual Report describing a focused strategy to develop disease‑modifying therapies for heart disease, centered on genetic drivers of cardiomyopathies. The company is advancing three clinical‑stage programs: gene therapies TN‑201 for MYBPC3‑associated hypertrophic cardiomyopathy and TN‑401 for PKP2‑associated arrhythmogenic right ventricular cardiomyopathy, and small‑molecule HDAC6 inhibitor TN‑301 for HFpEF and other cardiac and muscular disorders.
Interim Phase 1b/2 data suggest TN‑201 and TN‑401 can increase target protein expression and improve biomarkers and arrhythmia measures, with generally manageable safety. Tenaya also highlights broad platform capabilities in iPSC disease models, capsid engineering, cardiac‑specific promoters, and in‑house AAV manufacturing. A new multi‑target collaboration with Alnylam includes up to $10.0 million in upfront payments and up to $1.13 billion in potential milestones, reinforcing its role as a specialist partner in cardiovascular genetics. As of June 2025, non‑affiliate equity was valued at approximately $63.1 million, with 216,998,876 common shares outstanding as of March 2026.
Tenaya Therapeutics reported 2025 results showing tighter spending, new partnerships and a stronger balance sheet. Net loss narrowed to $90.6 million, or $0.59 per share, from $111.1 million, or $1.31 per share, in 2024 as operating expenses declined.
Cash, cash equivalents and marketable securities rose to $100.5 million as of December 31, 2025, helped by a December underwritten offering of 50,000,000 units at $1.20 per unit, generating net proceeds of $55.8 million. Together with an expected upfront payment from a new Alnylam collaboration, the company expects to fund operations into the second half of 2027.
Tenaya highlighted encouraging early clinical data from gene therapies TN‑201 for MYBPC3‑associated hypertrophic cardiomyopathy and TN‑401 for PKP2‑associated arrhythmogenic right ventricular cardiomyopathy, as well as preclinical results for TN‑301 in Duchenne muscular dystrophy models. Multiple data readouts and steps toward pivotal trial planning are anticipated during 2026.
Tenaya Therapeutics entered a major collaboration with Alnylam Pharmaceuticals to discover and validate novel gene targets for potential cardiovascular therapies. The parties will nominate 15 targets and run a 24‑month research program with in vitro and in vivo validation under an agreed plan and budget.
Alnylam will reimburse Tenaya’s full-time employee and out-of-pocket research costs and will take over all later development, manufacturing, regulatory and commercialization work for products from collaboration targets. Tenaya grants Alnylam an exclusive worldwide license to use collaboration targets and related know‑how.
Tenaya will receive an upfront payment of up to $10.0 million, subject to $500,000 reductions for up to eight company‑nominated targets that do not meet agreed standards, and is eligible for up to $1.13 billion in development, regulatory and sales‑based milestones tied to company‑nominated targets. The agreement includes target‑level termination mechanics, exclusivity limits on Tenaya’s own work on certain targets, standard IP protections, indemnities, and allows Alnylam to terminate the collaboration unilaterally with notice.
Tenaya Therapeutics’ major shareholder group, The Column Group affiliates, has updated its ownership and recent trading activity in the company’s common stock. Several Column Group funds now report no beneficial ownership, while TCG Opportunity III LP and related entities report beneficial ownership of 49,313,559 shares, representing 23.1% of the common stock based on 213,744,535 shares outstanding as of December 15, 2025.
The filing details a series of open-market sales in February 2026 by TCG III LP and TCG III-A LP. On February 20, 2026, they sold 245,965 and 277,769 shares, respectively, at a weighted-average price of $0.6149 per share. On February 23, they sold 143,709 and 162,291 shares at $0.5972 per share, and on February 24, they sold 309,228 and 349,212 shares at $0.6153 per share. On February 25, 2026, TCG III LP sold 1,649,281 shares and TCG III-A LP sold 1,862,545 shares at a weighted-average price of $0.5624 per share.
The filing notes warrants to purchase 53,571,426 additional shares of common stock held by TCG Opportunity III LP that are not exercisable within 60 days because of Beneficial Ownership Limitations. Managing partners Tim Kutzkey and Peter Svennilson are included as reporting persons and may be deemed to share voting, investment and dispositive power over the reported shares through the Column Group structure.
Tenaya Therapeutics’ major shareholder entities affiliated with The Column Group reported significant open‑market sales of common stock. Investment funds including The Column Group III, LP and related Opportunity funds sold a combined 4,170,266 shares of Tenaya common stock in indirect transactions.
The sales occurred on February 24 and 25 at weighted average prices of $0.6153 and $0.5624 per share, across multiple trades within disclosed price ranges. A related holding entry shows 49,313,559 shares of common stock held indirectly as of February 24, which reflects a large investment position by these affiliated funds.
COLUMN GROUP III, LP reported sales of common stock in TNYA-related transactions identified in a Form 144 notice. The filing lists multiple sales dated 02/10/2026 through 02/24/2026, including 1,904,115 shares on 02/11/2026 for $1,297,002.29 and 309,228 shares on 02/24/2026 for $190,267.99.
COLUMN GROUP III-A, LP reported proposed sales of common stock via Form 144 for Tenaya Therapeutics. The filings list multiple sale dates and share amounts with proceeds for each transaction.
Examples shown include sales of 2,151,458 shares on 02/11/2026 (proceeds $1,464,712.61) and 349,212 shares on 02/24/2026 (proceeds $214,870.14). The entries are presented as individual proposed sales by the reporting holder.
Column Group–affiliated investment funds, significant stockholders of Tenaya Therapeutics, reported open-market sales of an aggregate 829,734 shares of Common Stock on February 20 and 23. Reported weighted-average sale prices were about $0.61 per share, within disclosed ranges from $0.573 to $0.63.
The securities are held indirectly through entities including The Column Group III, LP, The Column Group III-A, LP and TCG Opportunity III LPPeter Svennilson and Tim Kutzkey, may be deemed to share voting and investment power but disclaim beneficial ownership except to the extent of their pecuniary interest.
Tenaya Therapeutics reported insider sales by Column Group III, LP in two transactions.
The filing lists a sale of 161,422 shares on 02/10/2026 for $131,736.49 and a sale of 1,905,115 shares on 02/11/2026 for $1,297,002.29.
Column Group III-A, LP filed a Form 144 reporting proposed sales of common stock in TENAYA THERAPEUTICS (TNYA), with recent sales disclosed. The filing lists prior transfers including 182,295 shares sold on 02/10/2026 and 2,151,458 shares sold on 02/11/2026.
The notice also lists earlier Series A purchases of 225,890 shares (07/31/2017) and 1,365,200 shares (12/20/2018) as origins of the holdings.